123944-75-2

Basic information

• Product Name: 3-(chloromethyl)-N-methylbenzamide
• Synonyms: 3-(chloromethyl)-N-methylbenzamide
• CAS NO: 123944-75-2
• Molecular Weight: 183.637
• Mol File: 123944-75-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-(chloromethyl)-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(chloromethyl)-N-methylbenzamide(123944-75-2)
• EPA Substance Registry System: 3-(chloromethyl)-N-methylbenzamide(123944-75-2)

Safety Data

• Hazardous Substances Data: 123944-75-2(Hazardous Substances Data)

Upstream product

• 593-51-1 methylamine hydrochloride 
• 31719-77-4 3-chloromethylbenzoic acid 
• 63024-77-1 3-(Chloromethyl)benzoyl chloride 
• 99-04-7 m-Toluic acid 
• 74-89-5 methylamine 

Downstream Products

• 123944-76-3 N-methyl-3-<<4-<(4-nitrophenyl)methyl>-2,5-dioxoimidazolidin-1-yl>methyl>benzamide 
• 220880-22-8 3-(1-methyltetrazol-5-yl)benzyl chloride 

Relevant articles and documents

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

N-alkanoylphenylalanine derivatives

Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.